Jackson · Seed–Growth · 9 people tracked
Also known as ALTA PARTNERS INVESTMENT MANAGER, L.P. · ALTA PARTNERS MANAGEMENT COMPANY, L.P. · Alta Partners NextGen
Investment thesis
Alta Partners believes the healthcare sector has reached an inflection point where technology and innovation enable greater integration among physicians, payers, and patients to deliver better outcomes. The firm holds that healthcare should ultimately serve patients, and it is dedicated to supporting entrepreneurs in building high-impact companies. Its portfolio and outcomes center on life sciences and biotechnology, including cell and gene therapies, precision medicines, and clinical-stage biopharmaceutical companies.
Source: firm website, verified Aug 25, 2026.
Team · 9 people
from the firm's website & public directories
What they invest in
from 42 of 68 portfolio companiesHealthtech ×26Biotech ×25Medical Devices ×11Digital Health ×9AI & Machine Learning ×6SaaS ×4Fintech ×3Deep Tech ×2
HQs:United States×32
Who they back
founder profiles across 12 portfolio companiesFounding team size:solo founder×82 founders×33 founders×1
Investments · 68 tracked
founders shown can be your intro pathBy year:2025 · 52024 · 52023 · 12022 · 12019 · 22018 · 12017 · 22016 · 22015 · 32014 · 22012 · 125 dated
HealthtechAndover, US
Waleed H. Hassanein(Executive Officer, Director)Stephen Gordon(Executive Officer)
BoardEdwin M. Kania, Jr.(Director)David Abrams(Director)Joseph S. Lacob(Director)Travis Rhodes(Director)
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.
BiotechHealthtechCarlsbad, US
Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)Alan Fuhrman(Executive Officer)
BoardRobert More(Director)Nina Kjellson(Director)in
Co-investorsBioBritNextech InvestCanaan Partners
Nasdaq-listed clinical-stage immunology company in San Francisco developing hepatitis B/D antivirals and licensed T-cell engagers.
BiotechSan Francisco, US
Herbert Virgin(Executive Officer)Howard Horn(Executive Officer)Robert More(Director)Thomas Daniel(Director)Dipchand Nishar(Director)Robert Perez(Director)
Co-investorsARCH Venture Partners
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtech
Anthony Fordin
Co-investorsLongitude Capitalabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation – JJDCNew Leaf Venture PartnersPappas Capital+2 more
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardJohn McKearn(Director)inPeter Moldt(Director)
Board seatDan JanneyFarah Champsi· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)RiverVest Venture PartnersSamsara BioCapitalRoche Venture Fund
Berkeley, US
Peter Calthorpe(Executive Officer, Director)
Board seatGarrett Gruener· per SEC Form D · $2M raise · filed Jul 2019
HealthtechPalo Alto, US
MARCEE M. MARONEY(Executive Officer)DAVID GRAVETT(Executive Officer)T. MICHAEL WHITE(Executive Officer)HAYLEY LEWIS(Executive Officer)DAVID M. RENZI(Executive Officer, Director)STEVEN BASTA(Director)
Board seatGuy Nohra· per SEC Form D · $4M raise · filed Mar 2015
Developing in vivo CAR-T cell therapies for cancer treatment
Cambridge, US
Board seatBob More· per SEC Form D
Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions.
BiotechHealthtechMedical DevicesPittsburgh, US
Suma M. Krishnan(Director)Krish S. Krishnan(Chairman & CEO)Suma Krishnan(President, Research & Development)inKrish Krishnan(Chairman & CEO)inDoug Norby(Director)Dino Rossi(Director)
Board seatDan Janney· per SEC Form D · $11.3M raise · filed Aug 2017
Co-investorsAvoro Capital AdvisorsFrazier Life Sciences
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)Christopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)
BoardAleks Radovic-Moreno(Director)in
Board seatDan Janney· per SEC Form D
Co-investorsLongwood FundMission BiocapitalDolby Family VenturesForbionService Provider Capital
Prolacta Bioscience manufactures 100% human milk-based nutritional products and fortifiers for premature and critically ill infants in hospital neonatal intensive care units.
BiotechHealthtechMedical DevicesCity Of Industry, US
Scott Elster(Executive Officer, Director)John M. Shields(Executive Officer)
BoardFrank Foster(Director)Martin Sutter(Director)David Brailer(Director)
Board seatDan Janney· per SEC Form D
Co-investorsAisling CapitalEssex Woodlands Healthcare PartnersFrontier Venture CapitalPROOF
Spiral Therapeutics is a clinical-stage pharmaceutical company developing therapies for balance disorders and hearing loss using its Minimally Invasive Cochlear System (MICS) drug delivery platform.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Hugo Peris(Founder & CEO)Eugene de Juan(Executive Officer, Director)Lawrence Fritz(Director)
BoardWARREN THALER(Director)JEAN-FREDERIC PAULSEN(Director)
Board seatGuy Nohra· per SEC Form D · $10.9M raise · filed Feb 2023
Co-investorsCatalio Capital Management
USGI Medical develops endoluminal surgical technologies, including a shape-lockable flexible endoscopic platform (TransPort), endoluminal suturing tools, and expandable suture anchors, for incision-free, minimally invasive gastrointestinal procedures.
HardwareHealthtechMedical DevicesSan Clemente, US
Tracy Maahs(Executive Officer)Scott Moonly(Executive Officer, Director)John Cox(Executive Officer)
BoardMike Chuisano(Director)George Abi-Chahine(Director)
Board seatGuy Nohra· per SEC Form D · $4M raise · filed Jun 2019
HealthtechSan Clemente, US
Jeff Swiecki(Executive Officer)Earl R. Fender(Executive Officer, Director)Robert Reitzler(Executive Officer)Jeffrey A. Swiecki(Executive Officer)Scott C. Lynch(Executive Officer)Jeffrey A. Swiecke(Executive Officer)
Board seatGuy Nohra· per SEC Form D · $5M raise · filed Jul 2015
Co-investorsH.I.G. CapitalH.I.G. HealthBridge Partners
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
DAVID GRYSKA(Director)VICENTE ANIDO(Executive Officer, Director)MURRAY GOLDBERG(Director)ANAND MEHRA(Director)BRIAN LEVY(Executive Officer)GERALD CAGLE(Director)
Co-investorsAvoro Capital AdvisorsForesite CapitalOUP (Osage University Partners)Sofinnova Ventures
BiotechCambridge, US
Tina Liu(Executive Officer, Director)David Cordo(Executive Officer)Erica Whittaker(Director)Steve Gillis(Director)
BoardBob More(Director)
Co-investorsARCH Venture Partners
Amplitude Therapeutics is a biotechnology company developing RNA-based medicines.
Biotech
Ark provides a customizable digital platform for venture capital and private equity firms to manage investor communications, performance reporting, and document sharing with their limited partners.
Enterprise SoftwareFintechSaaS
Co-investorsAcies InvestmentsAloft VCAmity VenturesArtis VenturesAsymmetric Capital PartnersAt One Ventures+21 more
Co-investorsARCH Venture PartnersDC Investment PartnersLongwood FundNextech InvestPathway to CuresAtlas Venture
Co-investorsLongwood Fund
Boston, US
Dan Adams(Executive Officer, Director)
BoardPete Hudson(Director)inBruce Herzfelder(Director)Mark Prather(Director)
Bioventus develops orthobiologics and pain treatment products for orthopedic care, offering therapies such as the StimRouter neurostimulation device for chronic peripheral nerve pain.
BiotechHealthtechMedical Devices
Co-investorsAmpersandEssex Woodlands Healthcare Partners
Developed pharmaceuticals for B-cell cancers and immune diseases; acquired by MedImmune for up to $175M.
Co-investorsLatterell Venture Partners
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical Devices
Co-investorsAisling CapitalAsset Management CompanyCanaan PartnersFrazier Life SciencesSanderling Ventures
Received FDA approval for Tracleer to treat pulmonary arterial hypertension.
PartnerDan Janney· led
Co-investorsFrazier Life SciencesSofinnova Ventures
BiotechSan Carlos, US
Anthony P. Ford(Executive Officer, Director)Benjamin Potter(Executive Officer)Henry Skinner(Director)Liam Ratcliffe(Director)
BoardRon Hunt(Director)Loretta Tse, Ph.D.(Director)
Co-investorsNew Leaf Venture Partners
Received FDA approvals for the enlighten and Secret RF microneedling systems for skin conditions.
DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.
BiotechHealthtechCambridge, US
Nenad Grmusa(Chief Executive Officer)John McCabe(Chief Financial and Operating Officer)
Co-investorsAstellas Venture Management LLCDC Investment PartnersLongwood FundPfizer Venture InvestmentsUTokyo Innovation Platform Co. Ltd.Insight Partners+1 more
DispatchHealth delivers in-home medical care and house call services, offering patients an alternative to emergency rooms and urgent care facilities for acute medical conditions.
Digital HealthHealthtechDenver, US
Dr. Mark Prather(Founder)Kevin Riddleberger(Founder)Dominic Bagnoli(Director)
BoardPete Hudson(Director)in
Co-investorsEcho Health VenturesOak HC/FTOptum VenturesQuesta CapitalSINEWAVE VENTURES
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a small molecule multi-kinase inhibitor that co-targets master regulators of cancer to trigger programmed cell death.
BiotechHealthtech
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
BiotechDeep TechMedical Devices
Mike Curtis, Ph.D.(President & Chief Executive Officer)
Co-investorsAltium CapitalEisai Innovation, Inc.Fresenius Medical Care VenturesKhosla VenturesLux Capital
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPKhosla VenturesOUP (Osage University Partners)b2ventureKendall Capital Partners
BiotechAnn Arbor, US
Antonio M. Gotto, Jr.(Director)Tim M. Mayleben(Executive Officer, Director)Gilbert S. Omenn(Director)Daniel Janney(Director)Dov A. Goldstein(Director)Roger S. Newton(Director)
PartnerDan Janney· led
Co-investorsAisling CapitalArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan PartnersLongitude Capital+2 more
Received FDA approvals for Vazculep and Akovaz to treat anesthesia-related hypotension.
Received FDA approval for Vyndamax and Vyndaqel to treat ATTR-CM cardiomyopathy.
Free Market Health operates a care-driven marketplace platform for the specialty pharmacy ecosystem.
B2B MarketplacesHealthtechSaaSPittsburgh, US
Joe Cardosi(Founder)in
Co-investorsQuesta Capital
Harbor provides electronic data capture (EDC) software for clinical trial teams, designed to reduce data entry time and enable remote monitoring to improve data quality and accelerate trial timelines.
HealthtechMedical DevicesSaaSSan Francisco, US
Albert Cai(Founder)inNathan H. Leung(Founder)in
Co-investorsY Combinator8VCDFOGeneral Catalyst
Harbor Plan provides automation software for independent professionals to manage their practices.
AI & Machine LearningFintechSaaSSales TechSan Francisco, US
Clinton A.(Managing Director)inRob Carrington(Head of Engineering)in
Co-investorsTechstarsTinySeed8VCDFOGeneral Catalyst
Crypto & Web3Enterprise SoftwareFintechSioux Falls, US
Co-investorsAndreessen HorowitzFuture Perfect VenturesKindred VenturesPantera Capital8VCDFO+2 more
Harbor builds an AI-powered baby monitor that provides real-time custom alerts and sleep insights, and operates with or without WiFi.
AI & Machine LearningConsumerHardware
Co-investorsCarnrite Ventures8VCDFOGeneral CatalystTrust Ventures
Harbor Health is a healthcare provider and insurance company operating clinics across Texas that offers primary care, specialty care, and health coaching alongside integrated insurance coverage.
HealthtechInsurTechAustin, US
Sterling Claiborne Johnston(Chief Medical Officer)Jeffrey Fisher(Chief Financial Officer)Eric Scott(Vice President)inKara Rios(Chief Financial Officer)
BoardPete Hudson(Director)inAnthony Miller(Director)in
Co-investors8VCHealth2047 Capital Partners LLCLemhi VenturesMartin VenturesBreyer CapitalCubit Capital+2 more
Oncology company that received FDA approval for Campath to treat B-cell chronic lymphocytic leukemia.
PartnerDan Janney· led
Pharma company acquired by Roche; received FDA approval for Esbriet to treat idiopathic pulmonary fibrosis.
Kelonia is a biotechnology company developing next-generation genetic medicines, with a focus on cell and gene therapy programs including in vivo approaches and oncology applications.
BiotechHealthtech
Kevin Friedman(Founder & Chief Executive Officer)in
Co-investorsHorizons Ventures
Kite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer.
BiotechHealthtechSanta Monica, US
Arie S. Belldegrun(Executive Officer, Director)Margo R. Roberts(Executive Officer)Cynthia Butitta(Executive Officer)Marc Better(Executive Officer)Rizwana Sproule(Executive Officer)
BoardJoshua A. Kazam(Director)
Co-investorsPontifax Venture Capital
Biosciences company acquired by Bristol-Myers Squibb.
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)Maria Fardis(CEO)Cadmus C. Rich(Chief Medical Officer)Elaine Stracker(General Counsel)
Co-investorsCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundBiotechnology Value FundCatalio Capital Management+2 more
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsCerity Partners Ventures5AM VenturesDCVC Bio
Digital HealthHealthtechWellness & Fitness
PatientsLikeMe operates an online platform where patients track their conditions, treatments, and symptoms and connect with others who share similar health experiences.
Digital HealthHealthtechSocialCambridge, US
Philippe Amouyal(Director)Jonathan White(Director)Justin Barstein(Director)Martin Coulter(Executive Officer, Director)Jay M. Tenenbaum(Director)James Heywood(Director)
Co-investorsOptum Ventures
Hangzhou-based gene-editing biotech developing immune-privileged cell therapies and xenogeneic organs for transplant and cancer.
Co-investorsARCH Venture PartnersLAVSequoia Capital
Received FDA approval for Elocta to treat Hemophilia A.
Transcarent operates a generative AI-powered health and care platform that combines medical, pharmacy, and point solutions to help people navigate the healthcare system and access on-demand care.
AI & Machine LearningDigital HealthHealthtech
Co-investorsThreshold VenturesAlly Bridge GroupGeneral CatalystGeodesic CapitalHuman CapitalKinnevik+2 more
Transcarent operates a generative AI-powered health and care platform that combines medical, pharmacy, and point solutions into a single member experience, helping people navigate the healthcare system and access on-demand care.
AI & Machine LearningDigital HealthHealthtechDenver, US
Co-investors7wire VenturesCorewell Health VenturesGeneral CatalystGeodesic CapitalGreatPoint VenturesHuman Capital+5 more
Pharmaceutical company acquired by Daiichi Sankyo.
United Musculoskeletal Partners is a physician-owned shared services organization that partners with musculoskeletal (MSK) physician practices, providing management services such as financial analytics, compliance, procurement, and value-based care support while practices retain clinical autonomy.
Digital HealthHealthtech
Co-investorsWCAS
Variant Bio is a therapeutics company that uses human genomics to guide drug development, drawing on expertise across genetics, molecular biology, therapeutics, anthropology, and ethics.
AI & Machine LearningBiotechDigital HealthNew York, US
Kaja Wasik(Executive Officer, Director)Andrew Farnum(Chief Executive Officer)Stephane Castel(Co-Founder, Chief Scientific & Technology Officer)inCraig Basson(Chief Medical Officer, President of R&D)Holly Vance(Chief Operating Officer)
BoardJulie Sunderland(Director)
Co-investorsGeneral CatalystLux CapitalSoftBank Vision FundDimension Capital
Vir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities.
AI & Machine LearningBiotechDigital HealthMedical Devices
Marianne De Backer(CEO)
Co-investorsARCH Venture PartnersSoftBank Vision Fund8VCSoftBank Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 9
IPOs and acquisitions across the tracked portfolioTransMedicsNASDAQ: TMDXTYRA BiosciencesNASDAQ: TYRAVir BiotechnologyNASDAQ: VIRCellective Therapeuticsacq. by MedImmuneHarboracq. by BitGoInterMune Pharmaceuticalsacq. by RocheKosan Biosciencesacq. by Bristol Myers SquibbPaladinahealthacq. by Marathon HealthU3 Pharmaacq. by Daiichi Sankyo
Portfolio news
latest coverage across their companiesTYRA Biosciences · stocktitan.net · Aug 14, 2026
Harbor · kiiitv.com · Jul 17, 2026
Harbor · kiiitv.com · Jul 17, 2026
Harbor · kiiitv.com · Jul 17, 2026
Vir · marketbeat.com · Jul 16, 2026
Harbor Health · finance.yahoo.com · Nov 13, 2025
Kite Pharma · partnology.com · Oct 21, 2025
Fund performance · per public LP disclosures · 7
as of Sep 2024| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Alta Partners VIIILPs: Employees' Retirement System of Rhode Island, Hawaii Employees' Retirement System | 2006 | — | 16.3% | 2.47x | 2.47x |
| Alta BioPharma Partners IIILPs: Employees' Retirement System of Rhode Island | 2003 | — | 5.8% | 1.50x | 1.42x |
| Alta BioPharma Partners II, L.P.LPs: California Public Employees' Retirement System | 2000 | — | 3.2% | 1.18x | 0.96x |
| Alta Subordinated Debt Partners IIILPs: The Regents of the University of California | 1993 | — | 28.8% | 3.40x | 3.40x |
| Alta Subordinated Debt Partners IILPs: The Regents of the University of California | 1988 | — | 12.1% | 2.12x | 2.12x |
| Alta Subordinated Debt PartnersLPs: The Regents of the University of California | 1986 | — | 8.6% | 1.88x | 1.88x |
| Alta Co PartnersLPs: The Regents of the University of California | 1980 | — | 13.6% | 2.22x | 2.22x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Alta Partners made?
- Alta Partners has 57 tracked investments, 7 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.
- What stage does Alta Partners invest at?
- Alta Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Alta Partners's typical check size?
- Alta Partners typically writes checks of $1M – $12M.
- What sectors does Alta Partners focus on?
- Alta Partners focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Alta Partners located?
- Alta Partners is headquartered in Jackson, US.
- Who does Alta Partners co-invest with?
- Alta Partners most often shares deals with ARCH Venture Partners, Longwood Fund, DC Investment Partners, among 81 tracked co-investors.
Media · Podcasts & interviews
featuring the teamPete Hudson, Alta Partners & Transcarent Investor, Part 1
The Health Care Blog's Channel · Pete Hudson
Jean Deleage - Alta Partners 2 5 2000
FRENCH AMERICAN TV ARCHIVES · Jean Deleage · youtube.com
Images
Co-investors · 17
Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.
.png)
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Questa Capital is a venture capital firm that partners with teams building next-generation healthcare companies focused on improving patient outcomes and reducing costs.
Insight Partners is an investment firm focused on accelerating revenue and profit growth in software companies, providing capital and operational support through its Insight Onsite team.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Frazier Healthcare Partners is a healthcare-focused private equity firm that partners with profitable, growing healthcare companies to drive scale and long-term value, pairing high-conviction investment themes with experienced executives.
RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.
Astellas Venture Management (AVM) is the wholly-owned corporate venture arm of Astellas, providing equity investments to private, early-stage biotechnology companies developing therapeutic programs and platform technologies for drug discovery.
Unknown Ventures is a venture studio based in Austin that provides funding and operational support to early-stage startups at the pre-seed to Series A stage. The firm backs founders seeking to create innovative solutions that improve human experience.
▶5 more co-investors
DCVC (Data Collective)Polaris PartnersS32Domain AssociatesAsset Management Ventures
Firms observed investing alongside Alta Partners, from public investor directories. Shared companies are the overlap with Alta Partners's recorded portfolio.
Similar investors
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
Hadean Ventures is a European venture capital fund manager with a track record in life sciences, investing across sectors and stages in science-driven innovation addressing real-world challenges.
Sciety (Sciety Venture Partners) is a Nordic investment firm that lets its members co-invest alongside it in life science and digital health companies, leading deals from initial dialogue through to funding.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Ally Bridge Group is a global healthcare investment manager focused on high-impact life sciences innovation across private and public markets.